AMP assesses clinical implementation of past standards and guidelines for interpretation and reporting of sequence variants in cancer
The Association for Molecular Pathology (AMP) has published a report that was designed to assess clinical adoption, identify classification inconsistencies, and evaluate implementation barriers for the 2017 report, “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.”
The AMP manuscript, “Assessments of Somatic Variant Classification Using the AMP/ASCO/CAP Guidelines” was released online ahead of publication in The Journal of Molecular Diagnostics.
To help standardize the interpretation and reporting of sequence variants in cancer, the 2017 guidelines were developed by a panel of experts and based on evidence from a comprehensive review of published literature, empirical data, current laboratory practice surveys, feedback from multiple public meetings, and professional experiences. The report proposed a four-tiered system to categorize somatic sequence variations based on their clinical significance in cancer diagnosis, prognosis, and/or therapeutics:
- Tier 1: Variants with strong clinical significance
- Tier 2: Variants with potential clinical significance
- Tier 3: Variants of unknown clinical significance
- Tier 4: Variants deemed benign or likely benign
To read the full manuscript, please visit: https://doi.org/10.1016/j.jmoldx.2022.11.002.
